Literature DB >> 25446684

[Treatments strategies for intracranial cavernomas].

Martin N Stienen1, Philippe Bijlenga2, Karl Schaller2, Gerhard Hildebrandt3, Oliver P Gautschi2.   

Abstract

Cerebral cavernomatous malformations (CCM) are a subgroup of low-pressure cerebral vascular malformation. They have an estimated prevalence of 0,1-4% of the population and account for 8-15% of all cerebral vascular malformations. Depending on their size and localization (supratentorial or infratentorial, brain stem), CCM may present with focal bleedings with or without neurological deficits, as epileptic seizures, or are diagnosed incidentally by MRI performed for unspecific symptoms (e.g. headache, vertigo), especially in younger patients (mostly in 2nd or 3rd decade). The decision-making in patients with CCM can be classified into four categories: surgical or conservative treatment of symptomatic or incidental lesions. The decision regarding the optimal therapy in the individual patient must be made in the knowledge of the natural history (risk for bleeding or epilepsy) on the one hand, and the surgical possibilities (accessibility of the lesion) including their estimated outcome on the other hand. Therefore, careful patient selection and appropriate experience of the centre is warranted in the management of CCM.

Entities:  

Keywords:  Kavernom; Management; Pathophysiologie; Therapie; angiome caverneux; cavernoma; cavernome; cavernous angioma; cerebral cavernomatous malformation; gestion; kavernöses Angiom; malformation cérébrale caverneuse; management; pathophysiology; physiopathologie; therapy; traitement; zerebrale kavernomatöse Malformationen

Mesh:

Year:  2014        PMID: 25446684     DOI: 10.1024/1661-8157/a001854

Source DB:  PubMed          Journal:  Praxis (Bern 1994)        ISSN: 1661-8157


  1 in total

1.  Routinely Performed Serial Follow-Up Imaging in Asymptomatic Patients With Multiple Cerebral Cavernous Malformations Has No Influence on Surgical Decision Making.

Authors:  Julia Velz; Martin Nikolaus Stienen; Marian Christoph Neidert; Yang Yang; Luca Regli; Oliver Bozinov
Journal:  Front Neurol       Date:  2018-10-11       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.